Leerink Partnrs Weighs in on REGENXBIO FY2024 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at Leerink Partnrs reduced their FY2024 EPS estimates for shares of REGENXBIO in a research report issued on Wednesday, February 19th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will earn ($4.93) per share for the year, down from their prior forecast of ($4.86). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s Q4 2024 earnings at ($1.34) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.88) EPS, FY2028 earnings at ($0.65) EPS and FY2029 earnings at $0.23 EPS.

Several other research firms also recently commented on RGNX. The Goldman Sachs Group downgraded shares of REGENXBIO from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $30.00 target price on shares of REGENXBIO in a research note on Tuesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a research note on Wednesday, January 15th. Raymond James started coverage on shares of REGENXBIO in a research note on Friday, February 7th. They issued an “outperform” rating and a $27.00 target price on the stock. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.45.

REGENXBIO Trading Down 3.0 %

RGNX opened at $6.72 on Monday. The company has a 50 day moving average of $7.63 and a 200 day moving average of $9.52. The company has a market cap of $332.94 million, a PE ratio of -1.34 and a beta of 1.29. REGENXBIO has a 12 month low of $6.44 and a 12 month high of $28.80.

Institutional Investors Weigh In On REGENXBIO

A number of large investors have recently modified their holdings of the stock. FMR LLC boosted its stake in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in REGENXBIO by 9.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company’s stock valued at $185,000 after acquiring an additional 1,982 shares during the period. Teacher Retirement System of Texas lifted its position in REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 2,088 shares during the period. DnB Asset Management AS lifted its position in REGENXBIO by 20.1% during the 4th quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 2,434 shares during the period. Finally, GAMMA Investing LLC lifted its position in REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,510 shares during the period. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.